Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 2 OPEN-LABEL, SINGLE ARM STUDY TO EVALUATE THE EFFICACY, PHARMACOKINETICS, AND SAFETY OF ETRASIMOD IN PEDIATRIC PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

NCT07470879 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT07470879
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07470879 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 2 OPEN-LABEL, SINGLE ARM STUDY TO EVALUATE THE EFFICACY, PHARMACOKINETICS, AND SAFETY OF ETRASIMOD IN PEDIATRIC PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Recruiting
Start date
May 28, 2026
Completion date
August 18, 2034
Enrollment
24 (estimated)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

colitis, ulcerative